

Registration Deadline April 5, 2024

Event registration is limited,
so please register early.
No refunds will be given
after April 5, 2024.



To register, scan QR code or visit <https://bit.ly/DDHM24>

Joint Accreditation

In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the International Association for Continuing Education and Training (IACET), American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC Part 2 points (and patient safety MOC credit) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit Statement

Physicians: Duke University Health System. Department of Clinical Education and Professional Development designates this live activity for a maximum of 12 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing: Duke University Health System. Department of Clinical Education and Professional Development designates this activity for up to 12 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System. Department of Clinical Education and Professional Development designates this activity for up to 12 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-24-090-L04-P/T



Contact/Questions

Beth Tanner, *Duke Cancer Network*
615 Douglas St. Suite 602, Durham, NC 27705
beth.tanner@duke.edu

Meet the Expert

An opportunity to converse with featured Duke experts in a collegial and personal atmosphere. Meet the expert sessions are for non-industry attendees, held Friday, April 12th and Saturday, April 13th from 2:15 p.m.- 3:00 p.m. in the Heyward room. New clinical developments, forthcoming research, challenging patients, and how to improve your long bunker shot, could all be topics discussed in this informal networking event.

Submit a Clinical Quandary

Do you have a unique or unusually challenging hematologic malignancy patient?

Patients may present with atypical symptoms, have particularly challenging co-morbidities, or have failed multiple lines of treatment. A new feature of Duke Debates 2024, Clinical Quandaries Panel, provides an exciting opportunity to have Duke Debate Speakers working in the field of hematologic malignancy discuss, review, and provide real world advice on the management of your own challenging hematologic malignancy patient.

To submit a case to be reviewed at the Duke Debates Hematologic Malignancies 2024 Conference, please click the [link](#) and provide relevant information. You will be notified by email when your case is accepted and will be discussed. **Case submission deadline is Friday, March 29, 2024.**

Hotel Information:




Scan QR code or click the link below.

<https://bit.ly/WestinHHIHotelReservations>

24th Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

The Westin
Hilton Head Island
Resort & Spa

Hilton Head, SC
April 12-14, 2024



Presented by: Duke Cancer Network in
collaboration with Duke Cancer Institute



24th Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

Overview

This annual event brings together experts in the field of Hematologic Malignancies to discuss advances in treatment and debate current treatment paradigms. The aim is to educate oncologists, hematologists, and the healthcare team regarding evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies.

New opportunities include 'Meet the Expert' engagement to connect attendees with nationally recognized experts and a Clinical Quandary Panel to discuss and debate challenging case scenarios submitted by attendees. In addition, an advanced practitioner mini session is offered.

Target Audience

This educational activity is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, pharmacists, nurse practitioners, physician assistants, fellows, nurses, and other health care professionals interested in the treatment of patients with hematologic malignancies.

Learning Outcomes

- Describe emerging data and recent advances in the management of hematologic malignancies
- Examine the use of recent advances in treatment through lectures, case-based debates
- Compare traditional and emerging treatment options in the management of hematologic disease
- Debate treatment options and management strategies
- Evaluate the role of CAR T - cell therapy in hematologic malignancies

Agenda

Thursday, April 11

6:00 p.m.

Reception in the Grand Ocean Terrace

Friday, April 12

Registration and Breakfast - Product Theater #1

7:00 a.m. to 2:00 p.m.

Session 1: ABC's of Lymphoma

Moderator: Danielle Brander, MD

Keynote Address: Can We Improve the Efficiency of Drug Development in Acute Myeloid Leukemia?
Harry Erba, MD, PhD

Case Presentation and Debate: CLL Relapse After BTKi: Patients Should Continue in Class vs. Switching Class
Danielle Brander, MD vs. Alexey Danilov, MD

Debate: Frontline Hodgkin Lymphoma Management in 2024: Time for a change? vs. Don't change a good thing
Christopher Kelsey, MD vs. Alexandra Stefanovic, MD

Debate: Mantle Cell Lymphoma; Is There Still a Role for Autologous Transplantation?
Timothy Fenske, MD, MS (Medical College of Wisconsin) vs. Mitch Horwitz, MD

Debate: DLBCL Bispecific Antibody vs. CAR T; Is There an Uncontested Champion?
Kami Maddocks, MD (Ohio State University) vs. Matthew McKinney, MD

Clinical Quandaries in CLL and Lymphoma
Danielle Brander, MD; Alexey Danilov, MD; Mitch Horwitz, MD; Christopher Kelsey, MD and Kami Maddocks, MD

Meet the Expert #1 Dilemmas in Lymphoma Management: Networking and Collaboration
Matthew McKinney, MD

5:30 p.m. Reception on the Ocean Front Deck

Speakers are Duke faculty experts unless otherwise noted.

Saturday, April 13

Registration and Breakfast - Product Theater #2

7:00 a.m. to 2:00 p.m.

Session 2: Leukemias / MDS / MPD

Moderator: Harry Erba, MD, PhD

Case Presentation: Intermediate AML
Harry Erba, MD, PhD

Debate: Eligible Patients with Intermediate Risk AML Should Receive Allogeneic Hematopoietic Stem Cell Transplantation in First Remission
Laura Michaelis, MD (Medical College of Wisconsin) vs. Ted Alyea, MD

Case Presentation and Debate: Doublets vs Triplets in Older AML Patients Unfit for IC
Harry Erba, MD, PhD vs. Nicholas Short, MD (MD Anderson)

Strategic Questions: Demystifying Sickle Cell
John Strouse, MD, PhD

Case Presentation and Debate: Should Ruxolitinib Be Considered First Line Therapy for All Patients with Myelofibrosis
Lindsey Rein, MD vs. Ruben Mesa, MD, FACP (Atrium Health)

The Psychology of Medical Decision Making
Rebecca Shelby, PhD

Clinical Quandaries in Leukemias and Myeloma
Harry Erba, MD, PhD, Cristiana Chase, DO, Lindsay Rein, MD, Ruben Mesa, MD, FACP, Laura Michaelis, MD

Meet the Expert #2: Networking and Collaboration
Dr. Erba, Dr. Horwitz and Dr. Rein

2:30 p.m. to 5:00 p.m.

Session 3: APP Specialty Session

Moderator: Therese Hennig, PA-C, MPAS

Recent Updates in CLL Treatment
Meredith Moorman, PharmD, BCOP, CPP

Low Grade Lymphoma: Identification and Management
Alexandra Stefanovic, MD

Emerging Care Strategies in CAR T
Jo Ann Liu, DNP, MSN-NP

Clinical Keys in Supporting Survivorship
Kim Slawson, MSN, FNP-C

Quality of Life and Sexual Health
Jill Barbour, MSN, MA, WHNP-BC

5:30 p.m. Reception Koi Pond Garden

Sunday, April 14

Registration and Breakfast - Product Theater #3

7:00 a.m. to 11:00 a.m.

Session 4: Multiple Myeloma

Moderator: Cristiana Chase, DO

Case Presentation and Debate: Optimal Induction Therapy and the Use of MRD Analysis for High-Risk Myeloma
Susan Bal, MD (Univ. of Alabama Medical Center) vs. Yubin Kang, MD

Case Presentation and Debate: CAR T vs. Transplant for R/R Myeloma
Taewoong Choi, MD vs. Cristiana Chase, DO

The Future of Myeloma: Is it Nutrivention?
Urvi Shah, MD (MSKCC)

T-Cell Directed Therapy: Infectious Risk and Prophylaxis
Julia Messina, MD